Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Cancer. 2020 Jul 22;126(19):4289–4293. doi: 10.1002/cncr.33073

Table 3:

Response for 204 evaluable patients as reported by best response on clinical trial by RECIST criteria.

N %
Complete Response (CR) 2 1
Partial Response (PR) 28 13.7
Stable Disease (SD) 68 33.3
Progressive Disease (PD) 106 52
Overall Response Rate (ORR) 14.7